Peter Friedli , was co-founder of Osiris and, except for the period between February and June 2004, has been a director since January 1996. He has been a principal of the investment-banking firm Friedli Corporate Finance, Inc. since 1986. Friedli Corporate Finance, Inc., a leading Swiss venture capital firm, has made significant investments in the biotechnology industry. Friedli Corporate Finance, Inc. has been the primary source of financing for Osiris. Mr. Friedli is also President of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Prior thereto, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. Mr. Friedli is a director of E-centives, Inc., a publicly traded provider of interactive database marketing technologies and services. He also serves as a director in certain private companies.
C. Randal Mills, Ph.D., President and Chief Executive Officer, began his service for Osiris in July 2004. Dr. Mills is also a member of the Board of Directors. Prior to joining Osiris, Dr. Mills was an executive officer of Regeneration Technologies, Inc. (NASDAQ—RTIX). Dr. Mills served in several leadership positions at RTI from its formation in 1998 until 2004, including Vice President of Business Development and Vice President of Operations and R&D and is credited with several key initiatives including the development and commercialization of RTI's core technology, BioCleanse®. Prior to RTI, Dr. Mills was a member of the founding management team of the University of Florida Tissue Bank, Inc. The University of Florida Tissue Bank was the predecessor company to RTI. Dr. Mills received a bachelor's degree in microbiology and cell science and a Ph.D. in drug development, both from the University of Florida.
Felix Gutzwiller , M.D., Dr.P.H., elected to the Board of Directors in 2003, is Professor and Chairman of the Department of Public Health of the University of Zurich Medical School. Dr. Gutzwiller is also an elected member of the Swiss Parliament. Dr. Gutzwiller received a medical degree from the University of Basel in 1974 and did his post-graduate training at both Harvard University and Johns Hopkins University. He received his Dr.P.H. from the Johns Hopkins University School of Hygiene and Public Health in 1977. Dr. Gutzwiller has received many honors and awards over the years in the health profession.
Jay M. Moyes, elected to the Board of Directors in 2006, has served as the Chief Financial Officer of Myriad Genetics, Inc. since June 1996. Mr. Moyes previously served as Myriad's Vice President of Finance from July 1993 until July 2005. From 1991 into 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. degree from the University of Utah, a B.A. degree in economics from Weber State University, and is a Certified Public Accountant. Mr. Moyes has also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006.
Hans Klingemann, M.D., Ph.D., elected to the Board of Directors in 2012, is the Director of the Bone Marrow and Stem Cell Transplant Program at Tufts Medical Center in Boston, and a Professor of Medicine at Tufts University Medical School. He also directs the Hematological Malignancies Program at the Tufts Medical Center Cancer Center and runs a stem cell transplant research laboratory. Previously, Dr. Klingemann was director of Bone Marrow Transplant and Cell Therapy at Rush University Medical Center, and founding director of the Sramek Center for Cell Engineering in Chicago, Illinois. He has worked as a physician, scientist, educator and administrator in leadership positions for over twenty years at various academic medical centers and has authored over 150 scientific and medical papers.
Stock transaction information provided by EDGAR Online. Osiris Therapeutics, Inc. makes no representations or warranties with respect to the information contained herein and takes no responsibility for supplementing, updating, or correcting any such information. This listing does not include non-monetary transactions, such as stock option grants or shares purchased through the employee stock purchase plan. For recent transactions including non-monetary transactions, see our Section 16 SEC filings page.
Contact the Board
You can contact Osiris Therapeutics Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
Corporate Secretary
Osiris Therapeutics, Inc. 7015 Albert Einstein Drive Columbia, MD 21046 United States
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Osiris Therapeutics, Inc. Board of Directors has requested that certain items which are unrelated to the duties and responsibilities of the Board should be excluded, such as:
Product complaints
Product inquiries
New product suggestions
Resumes and other forms of job inquiries
Surveys
Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
= Chairman of the Board
= Chair 
= Member
= Independent Director
Board of Directors
Governance Documents